Additional Supporting Information may be found in the online version of this article. “
“The roots of research into gastritis
go back into the early decades of the 20th century. Modern aspects of its classification and knowledge of its biological course and consequences were relatively well known even at the time that Helicobcter pylori was discovered by Robin Warren and Barry Marshall in 1982. This discovery, however, significantly changed the field, establishing that the commonest form of gastritis is selleck simply an infectious disease, a finding that raised enormous interest in the subject amongst gastroenterologists, microbiologists, pathologists and basic researchers. However, many of these “new” players in the field often had a limited knowledge of the morphological aspects of gastric inflammations and chronic gastritis. As a consequence in the late 1980′s a Working Z-VAD-FMK mouse Party was set up to review the biology and natural course of chronic gastritis, to propose a new classification for
gastritis, and to provide simple guidelines for reporting the pathology of gastritis in endoscopic biopsies in an attempt to bring uniformity to the subject and facilitate comparative studies in what was to be an era of high research activity. These guidelines, The Sydney System: A New Classification of Gastritis was presented to the World Congress of Gastroenterology in Sydney in 1990, and was later published as six papers in the Journal of Gastroenterology and Hepatology.
Now, twenty years on, this review looks back on the birth of Sydney System and why it is still important and successful. Twenty years ago, at the World Congress of Gastroenterology in Sydney in 1990, a working party presented the Sydney System: A New Classification of Gastritis which was subsequently published as six papers in the Journal Gastroenterology and Hepatology.1–6 上海皓元 These encompassed the pathology, the endoscopic aspects, the microbiology, autoimmunity and epidemiology of chronic gastritis. The System was a major focus of attention at the Sydney congress and gained even more attention afterwards. The Working Party presentation had been carefully prepared in many pre-meetings, and the whole clinico-pathological consensus process was orchestrated by two initiators Professors George Misiewicz and Guido Tytgat. A Dutch pharmaceutical company, Gist-Brocades, kindly provided financial support that facilitated the numerous preparatory pre-Sydney World Congress meetings that were the essential basis for the final success. In those days the company marketed bismuth as a drug for the treatment of Helicobacter pylori—an option that still is valid. Even though a considerable amount was already known about gastritis itself, and about its natural course and disease associations, after the discovery of H. pylori by Robin Warren and Barry Marshall in 1982,7 the approach to the understanding of gastritis and upper gastrointestinal disease changed markedly.